The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | How can biomarker findings guide treatment algorithms in G/GEJ cancers?
Paolo Manca, MD, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy, discusses how biomarker findings could be used to guide treatment algorithms in advanced gastric and gastroesophageal (G/GEJ) cancers following results from the ARMANI (NCT02934464) trial. In biomarker-negative patients, it may be acceptable to provide more toxicity using paclitaxel-based chemotherapy with oxaliplatin as these patients cannot be offered targeted treatments. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
